@travizack.bsky.social and Varun from OE talk AI and the future of medical information on the STAT-AI podcast: open.spotify.com/episode/121y...

Happy first day! To all interns, residents, fellows, and new attendings. We are building specialty specific learning communities at OE. If you are interested in joining peers and learning together with Openevidence, shoot us an email at [email protected]

Dr. Atul Butte was laid to rest today. His large shoulders and larger vision have been foundational to all AI can and will accomplish in healthcare. His family is requesting those interested to please consider supporting research on mpnst here: giving.ucsf.edu/fund/maligna...

👋 Our editors are on-site at #ASCO25, Chicago. We’re excited to be part of this gathering of global cancer experts—come & meet us. ‘Contact the Editor’ details below, in-thread 🧵 @ascocancer.bsky.social

Hello from the City of Lakes! We’re thrilled to welcome thousands of members of the ob-gyn community to the 2025 Annual Clinical & Scientific Meeting. From the heart of the Midwest, we’re kicking off a weekend of connection, learning, and inspiration. Share the excitement using #ACOG2025!

As for the safety, I asked @openevidence.bsky.social which is a chatbot trained on the professional medical literature. The current thinking is that it is not ready for primetime. www.openevidence.com/ask/2ca4fd30...

we are now offering free CME credits just by OE in yuour normal practice: www.openevidence.com/announcement...

So thrilled to welcome this extraordinary group of 64 young physicians to @UCSF and @UCSFimresidency. A great day! (UCPC=UCSF Health-based primary care program; SFGH=San Francisco General-based primary care; PSTP=physician-scientist training program) @UCSFIMChiefs @UCSFDOM

@travizack.bsky.social and Varun from OE talk AI and the future of medical information on the STAT-AI podcast: open.spotify.com/episode/121y...

Some background on current limited TX options: www.openevidence.com/ask/a94c01ac... However, there is a recently opened clinical trial for this rare disease clinicaltrials.gov/study/NCT061... @jerryclee.bsky.social

Some mechanistic background: www.openevidence.com/ask/07ad3d33...

A short review of where we were at prior to this trial www.openevidence.com/ask/1e95f6d9...

In a new phase 2 trial, researchers evaluated the efficacy of a gene-editing therapy, NTLA-2002, in preventing angioedema attacks in patients with hereditary angioedema. Full trial results and Plain Language Summary: nej.md/4heR7hT #MedSky #Oncology

As a primary care doctor & clinical informatician, I love using @openevidence.bsky.social during my clinic visits to review latest guidelines with patients & sources. I strongly believe this practice helps build stronger therapeutic relationship with the doctor + AI assisted CDS. #CI=AI

Other prior trials looking at the pros and cons of bridging AC peri-procedures www.openevidence.com/ask/67491f3f...

We do keep our index updated daily so the most recent cdc pubs and mmwr will continue to be available for answers even if removed from CDC website

These A.I. models are rapidly changing life science. A brief, open-access review of the remarkable progress in @science.org this week www.science.org/doi/10.1126/...

For whom it make concern, with recent disruptions to CDC published information, we keep our index of this information updated daily, so will always have the most updated recommendations

Nature research paper: Expanding the human gut microbiome atlas of Africa https://go.nature.com/42x1t7S

Painful, chronic peripheral neuropathy from cancer chemotherapy is common, especially from platinum-based drugs and taxanes, as reported today in a meta-analysis of 77 studies from 28 countries

In a 54-year-old male athlete, echocardiograms obtained 3 weeks after diagnosis of AL amyloidosis showed classic features of amyloid cardiomyopathy and evidence of progressive disease. Read the full case details: nej.md/3WpUsC8 #MedSky #CardioSky

OpenEvidence. Hadn’t heard of the other two.